Google Search Trends to Assess Public Interest and Concern About Pegcetacoplan for the Treatment of Geographic Atrophy.

IF 0.9 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2024-08-01 Epub Date: 2024-05-01 DOI:10.3928/23258160-20240409-04

Hana A Mansour, David Xu, Michael N Cohen, Jordan D Deaner, Jason Hsu, Yoshihiro Yonekawa, Anton Orlin, Meera D Sivalingam, Jayanth Sridhar, Ajay E Kuriyan

{"title":"Google Search Trends to Assess Public Interest and Concern About Pegcetacoplan for the Treatment of Geographic Atrophy.","authors":"Hana A Mansour, David Xu, Michael N Cohen, Jordan D Deaner, Jason Hsu, Yoshihiro Yonekawa, Anton Orlin, Meera D Sivalingam, Jayanth Sridhar, Ajay E Kuriyan","doi":"10.3928/23258160-20240409-04","DOIUrl":null,"url":null,"abstract":"Objective: To assess global trends in interest surrounding the newly Food and Drug Administration (FDA)-approved treatment for geographic atrophy, (GA), Syfovre (pegcetacoplan), and related searches.Methods: We utilized Google Trends, in order to gauge the public interest in Syfovre from October 16, 2022, to October 8, 2023.Results: Notable spikes in relative search volumes (RSV)s for \"Syfovre\" were observed in mid-to-late February 2023, and in March and April 2023, coinciding with the drug's FDA approval and introduction to the market. Of the various side effects, retinal vasculitis garnered the most significant attention, with a sharp rise in RSV in mid-July 2023. Geographic variation was evident, with the highest RSVs for \"Syfovre\" originating from users on the East Coast.Conclusion: Google Trends proves to be a useful tool for gaining insight into public interest in pegcetacoplan as a treatment for GA. [Ophthalmic Surg Lasers Imaging Retina 2024;55:452-460.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"452-460"},"PeriodicalIF":0.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20240409-04","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess global trends in interest surrounding the newly Food and Drug Administration (FDA)-approved treatment for geographic atrophy, (GA), Syfovre (pegcetacoplan), and related searches.

Methods: We utilized Google Trends, in order to gauge the public interest in Syfovre from October 16, 2022, to October 8, 2023.

Results: Notable spikes in relative search volumes (RSV)s for "Syfovre" were observed in mid-to-late February 2023, and in March and April 2023, coinciding with the drug's FDA approval and introduction to the market. Of the various side effects, retinal vasculitis garnered the most significant attention, with a sharp rise in RSV in mid-July 2023. Geographic variation was evident, with the highest RSVs for "Syfovre" originating from users on the East Coast.

Conclusion: Google Trends proves to be a useful tool for gaining insight into public interest in pegcetacoplan as a treatment for GA. [Ophthalmic Surg Lasers Imaging Retina 2024;55:452-460.].

查看原文本刊更多论文

通过谷歌搜索趋势评估公众对用于治疗地理萎缩症的 Pegcetacoplan 的兴趣和关注。

目的：评估全球对美国食品药品管理局（FDA）新近批准的治疗地理萎缩（GA）的药物Syfovre（培西他康）的兴趣趋势以及相关搜索：我们利用谷歌趋势（Google Trends）来衡量公众从2022年10月16日至2023年10月8日对 "Syfovre "的兴趣：2023年2月中下旬以及2023年3月和4月，"Syfovre "的相对搜索量（RSV）出现了明显的峰值，这与该药物获得美国食品及药物管理局批准并投放市场的时间相吻合。在各种副作用中，视网膜血管炎最受关注，2023 年 7 月中旬 RSV 急剧上升。地域差异明显，"Syfovre "的RSV最高值来自东海岸的用户：事实证明，谷歌趋势是了解公众对培高氯普兰治疗 GA 的兴趣的有用工具。[Ophthalmic Surg Lasers Imaging Retina 2024;55:XX-XX.].

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.